Table 3.
Ongoing trials with new BRSs.
| Device | Clinical trials identifier | Recruitment status | Actual study start date | Estimated study completion date | Study type | Enrollment | Allocation | Masking | |
|---|---|---|---|---|---|---|---|---|---|
| FANTOM II | FANTOM | NCT02539966 | Recruiting | Mar-2015 | Mar-2023 | Interventional | 220 | Non-randomized | None (open label) |
| MeReS100-China | MeRes100; XIENCE EES | NCT03454724 | Active, not recruiting | Jan-2020 | Dec-2024 | Interventional | 484 | Randomized | None (open label) |
| RENASCENT | FORTITUDE | NCT02255864 | Active, not recruiting | Feb-2015 | Nov-2020 | Interventional | 21 | N/A | None (open label) |
| RENASCENT II | APTITUDE | NCT02568462 | Active, not recruiting | Nov-2015 | Jul-2021 | Interventional | 60 | N/A | None (open label) |
| FUTURE-I | Firesorb | NCT02659254 | Active, not recruiting | Jan-2016 | Oct-2021 | Interventional | 45 | N/A | None (open label) |
| FUTURE-II | Firesorb | NCT02890160 | Recruiting | Aug-2017 | Oct-2023 | Interventional | 610 | Randomized | Single (participant) |
| MAGMARIS | Magmaris | NCT03413813 | Active, not recruiting | Jul-2017 | May-2021 | Observational | 445 | Not applicable | Not applicable |
| BIOSOLVE-IV | Magmaris | NCT02817802 | Recruiting | Aug-2016 | Oct-2025 | Observational | 2054 | Not applicable | Not applicable |
| BESTMAG | Magmaris | NCT03955731 | Recruiting | Feb-2019 | Feb-2022 | Interventional | 100 | N/A | None (open label) |
| IBS-FIM | IBS | NCT03509142 | Active, not recruiting | Apr-2018 | Dec-2024 | Interventional | 65 | N/A | None (open label) |
EES, everolimus-eluting stent; IBS, iron bioresorbable scaffold; N/A, not available.